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RESEARCH ARTICLE
Major Congenital Metabolic Disorders in the First 12 years of Life in 79,100 
Consecutively Born Children in Qazvin Province
Abstract
Objective 
Deficient enzyme activity may cause congenital metabolic defects. These defects 
are inherited in an autosomal recessive, autosomal dominant, and X-linked 
patterns. This study was aimed at investigating the occurrence of metabolic 
diseases in Qazvin Province.
Materials & Methods
This cross-sectional study was performed on 79,100 children aged 12 years or 
less between 2000 and 2010. Clinical manifestations, laboratory findings, and all 
other essential information were assessed to precisely diagnose the metabolic 
diseases. The sorted information on congenital metabolic defects of the patients, 
information included in a checklist, and data were analyzed using SPSS.
Results
A total of 57 metabolic disorders were recorded. The difference in the prevalence 
of metabolic disorders between male (29 cases) and female (28 cases) was 
not statistically significant. The most frequent congenital metabolic disorder 
among our patients was phenylketonuria (PKU; 5 per 1,000 cases), and the least 
common disorder was galactosemia (3 per 1,000 cases).
Conclusion
Timely detection and management of congenital metabolic disorders can 
help save the affected children. Prenatal screening programs, molecular gene 
therapy, and counseling for consanguineous marriage can play important roles 
in reducing the rate of metabolic disorders in this province.
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Introduction
Congenital metabolic defects develop when a specific functional enzyme is 
absent, and this can be caused by several mechanisms (1). More than 350 different 
congenital metabolic diseases have been described to date, most of which are 
rare (2). A recent survey conservatively estimated that the incidence of metabolic 
disorders is approximately 1/2,500 births or 10% of all monogenic conditions in 
children (3) Most metabolic disorders are congenital and inherited in an autosomal 
recessive pattern, i.e., the disorder develops when two mutant alleles are present. 
The carrier state is usually not associated with morbidity (4). However, children 
born of a consanguineous marriage are at an increased risk of developing metabolic 
disorders and of early mortality (5). With a decrease in the incidence of fatal 
infectious diseases, congenital metabolic defects may be one of the main causes 
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of infant mortality in the future. Because large systemic 
studies of metabolic disorders have not been performed 
in Iran, we assessed the prevalence rate of metabolic 
diseases in patients who admitted to hospitals in Qazvin 
province with congenital complaints.
Materials & Methods
We designed a prospective cross-sectional study to 
evaluate disease prevalence, causes, and clinical 
presentation in 79,100 patients aged 12 years or less who 
were registered at the genetics division of the Ghods 
Major Pediatric Hospital between 2000 and 2010. We 
chose this hospital because it is affiliated to Qazvin 
University of Medical Sciences and provides emergency 
services to a large part of the province. Furthermore, 
demographic information and clinical findings at birth 
were collected from the maternal records maintained at 
Kosar Hospital as well as from the parents at the initial 
patient evaluation from 2000 to 2004. Patients were 
referred to us because of neurological signs, seizures, 
mental retardation, jaundice, organomegaly, and skeletal 
disproportion.
The metabolic diseases in the probands were confirmed 
by reviewing of the pedigree of the family and the 
family’s genetic records; population screening; review 
of the mode of inheritance; assessment by geneticist; 
assessment of the patients’ clinical characteristics, 
including complete blood count, creatinine level, FBS, 
calcium level, electrolyte levels, plasma TSH level, 
total and direct bilirubin levels, liver transaminase level, 
creatine kinase level, alfa fetoprotein level, urinary 
amino acid levels, reticulocyte count, and lipid profile; 
fluorescent spot test screening; high-performance liquid 
chromatography determination of plasma amino acid 
levels, and assessment of Guthrie test findings. Plasma 
acylcarnitine profile and urine organic acid levels were 
assessed if metabolic acidosis, hyperammonemia, 
and lactic acidosis were detected. On the basis of the 
diagnosis, the patients were classified into 3 categories 
(Table 1). Disease incidence rate per 1,000 patients 
was calculated. Patient data were analyzed using SPSS 
software (v.11.5; Chicago, IL).
Results
This study presents the results, frequencies, and analyses 
of congenital metabolic disorders of 57 of the 79,100 
children. The diagnoses are summarized in Table 1. 
The prevalence of metabolic diseases was 0.072% 
(57 cases), with no statistically significant difference 
between the prevalence in male (29 cases) and female 
(28 cases). The results were double-checked using 
hospital registration information related to the study 
period (Fig. 1). 
Discussion   
The results of the present study are discussed in light of 
our recent findings (from 2000 to 2004) (6) of increased 
incidence of congenital metabolic diseases in Qazvin 
Province. 
The most frequent disorder among our patients was 
phenylketonuria (PKU) (41 patients, 0.05%) (Figure 
1). The frequency of PKU is approximately 1 in 10,000 
births (7). However, the rate of PKU in this study 
(0.05%) was less than the previously reported rate. The 
enzyme responsible for the disorder is phenylalanine 
hydroxylase, which catalyzes the hydroxylation of 
phenylalanine to tyrosine in healthy individuals. In the 
absence of this enzyme, phenylalanine levels increase, 
which is believed to be toxic. PKU is the most common 
congenital metabolic disorder in Tehran (8), Fars 
Province (9,10), Mashhad (11), and Isfahan (12). The 
incidence of PKU in Iran is higher than that reported in 
other countries (12).
Classic galactosemia occurs in approximately 1 in 
60,000 live births. However, the incidence varies from 
1 in 30,000–40,000 live births in Europe (13) to 1 in 1 
million live births in Japan(14); the estimated incidence 
in the U.S. is 1 in 53,000 live births (15). In our report, 
the prevalence of galactosemia in the referred patients 
was approximately 1 in 27,000, a rate that is lower than 
that observed in previous studies in other countries.
The incidence rate reported for all types of 
mucopolysaccharidosis (MPS) ranges from 1 in 25,000 
to 1 in 46,000 live births (16). Thirteen patients of 
the 79,100 symptomatic patients who were assessed 
for congenital metabolic disorders had MPS, and the 
prevalence rate was 1 in 6,000 among the referred 
patients. This incidence and prevalence rate are lower 
than the corresponding values reported in the general 
population. 
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In this study, a large number of patients (68%) were 
children born from consanguineous marriages. We 
recommend that prenatal diagnosis be offered to 
consanguineous couples with recessive genes, since 
there is a 25% risk of the child being affected. In some 
countries, the current percentage of consanguineous 
marriages is higher and even exceeds 50%,while 
in many others, the percentage is not more than 
1% (17,18). Many researchers have indicated that 
consanguinity causes autosomal recessive/metabolic 
disorders (4,19). On the basis of the findings obtained 
in our previous study, we estimated the incidence of 
congenital metabolic disorders to be higher in children 
born of consanguineous marriages (38.57%) than 
in children born of non-consanguineous marriages 
(7.26%) (20). Every year, over 130 million infants 
are born worldwide (18), and  13.5 million of these 
children are born of consanguineous marriages.
Taking the above findings into account, we concluded 
that newborn screening, prenatal diagnosis for congenital 
metabolic disorders, and somatic gene therapy can help 
treat affected infants. In addition, molecular screening 
has opened new avenues of diagnosis and become a 
promising new means for treatment. Various other 
factors, such as different geographical distribution, 
ethnicity, diet, socioeconomic differences, and 
consanguineous marriage should be considered for 
the accurate diagnosis and treatment of congenital 
metabolic disorders.
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Fig 1. Number of cases of congenital metabolic disorders in our study
 




















0.0037 3 1 2 Galactosemia 
0.016 13 8 5 MPS 
0.050 41 19 22 PKU 
0.072 57 28 29 Total 
MPS: Mucopolysaccharidosis, PKU: Phenylketonuria
MPS: Mucopolysaccharidosis, PKU: Phenylketonuria,Gal: Galactosemia
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